Recent Updates in Lower-Risk MDS
In the third article of this series, Amer Zeidan, MBBS, MHS, reviews recent data in lower-risk myelodysplastic syndrome and discusses the evolving treatment landscape.
Updates in the Management of Lower-Risk MDS
Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.
Zeidan Recaps the Phase 3 IMerge Trial of Imetelstat in Lower-Risk MDS
Amer Zeidan, MBBS, discusses the rationale of studying imetelstat in the phase 3 IMerge trial in patients with lower-risk myelodysplastic syndrome.
Clinical Implications and Positioning of Imetelstat in Lower-Risk MDS
Closing remarks on the overall clinical implications of imetelstat data, and patient populations that could benefit the most from it.
Insights on Imetelstat in Lower-Risk MDS: Safety Outcomes
Insights on patient-reported fatigue from the IMerge trial, reviewing imetelstat data and its potential to address an unmet need in lower-risk MDS.
Disease Modifiying Therapy in Lower-Risk MDS
A closer look at disease modifying treatments in MDS, providing insights into their mechanisms of action and impact on the management of the disease.
1-Year Follow-up of Efficacy Data and Safety Outcomes of Imetelstat in Lower-Risk MDS
Expert oncolgists examine 1-year follow-up data from the IMerge trial, discussing the durability of response (transfusion independence), the impact of imetelstat on hemoglobin levels, key safety outcomes and managing cytopenias.
Clinical Implications of the COMMANDS Trial in the Treatment of Lower-Risk MDS
Amer Zeidan, MBBS, closes his discussion with a look at the potential implications of the COMMANDS trial data on the treatment of lower-risk MDS in clinical practice.
Luspatercept for Patients With Lower-Risk MDS: Data from the COMMANDS Trial
Dr Amer Zeidan details the design, patient population, and key efficacy and safety data from the phase 3 COMMANDS trial investigating luspatercept for the frontline treatment of lower-risk MDS with anemia.
Historical First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia
Amer Zeidan, MBBS, explains the treatment options for patients with lower-risk MDS prior to the approval of luspatercept.
Imetelstat in Lower-Risk MDS: IMerge Trial Overview and Efficacy Outcomes
An overview of the patient population and study design of the IMerge trial evaluating imetelstat, highlighting its MOA and rationale for its use in MDS, and reviews key efficacy outcomes, including HgB levels and transfusion independence.
First-Line and Second-Line Treatment Options for Lower-Risk MDS
Dr. Zeidan discusses first-line treatment options and the role of ESAs, while Dr. Savona reviews second-line treatment options and factors influencing treatment decisions in lower-risk MDS.
Defining and Assessing Risk in Patients with Myelodysplastic Syndrome
Dr Savona and Dr. Zeidan define lower- vs higher-risk MDS, describe their approach to risk stratification, and share how assessing risk is critical for developing treatment plans for patients.
Understanding Myelodysplastic Syndrome: Molecular Mechanisms and Diagnosis
Michael Savona, MD and Amer Zeidan, MBBS review the biology underlying myelodysplastic syndrome and explain the patient journey from symptom presentation to official diagnosis.
Risk Stratification in MDS
Dr Amer Zeidan explains the criteria he uses to assess risk in MDS, and why it is important to initiate treatment for lower-risk patients early.
Diagnosing Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Amer Zeidan, MBBS, discusses the signs and symptoms of lower-risk MDS and the tests typically used for diagnosis.
2 Clarke Drive Cranbury, NJ 08512